Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

Researchers said the drugs could make a major difference for chronic kidney disease patients by helping to reduce other risk ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also ...

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...

The likes of Wegovy and Ozempic could reduce the risk of kidney deterioration and failure by a fifth, a major study found.

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19, researchers found.